Immunotherapies for the treatment of advanced HCC generally involve an anti-PD-1/PD-L1 agent as monotherapy or in combination with an antiangiogenic or anti-CTLA-4 agent [3]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.